Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOKX76)

• Drug Name: Efomycine M Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMOKX76

Molecule-Related Drug Atlas

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[2]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[3]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[4]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[5]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[6]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[7]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[8]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[9]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[11]

Drug(s) Targeting E-selectin (SELE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[3]
GMI-1271	DMDTGWQ	Acute myeloid leukaemia	2A60	Phase 3	[12]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[5]
Bimosiamose	DM0TH9A	Atopic dermatitis	EA80	Phase 2a	[13]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[14]
PF-07209326	DM7YRAL	Sickle-cell disorder	3A51	Phase 1	[15]
GI-270384X	DM3KN2Q	Inflammatory bowel disease	DD72	Terminated	[16]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[17]
O-Sialic Acid	DMCAR7B	Discovery agent	N.A.	Investigative	[18]
1na	DM0A1YI	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E-selectin (SELE)	TTAU4D6	LYAM2_HUMAN	Inhibitor	[1]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[1]

References

• [1] Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.
• [2] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [3] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [4] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [5] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [6] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [7] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [8] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [9] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [10] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [11] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [12] Clinical pipeline report, company report or official report of glycomimetics.
• [13] Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
• [14] Clinical pipeline report, company report or official report of GlycoMimetics.
• [15] ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
• [16] Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
• [17] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [18] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.